Effect of Isorhamnetin on Inhibition of RANKL-induced Osteoclast Differentiation

Yongjin Lee, Holim Jin, Yoon A. Shin, Eun Young Lee, Sang Jip Nam, Young Jin Son

Research output: Contribution to journalArticlepeer-review


The elderly population is increasing worldwide. Osteoporosis, one of the diseases of the elderly, is a disease that occurs due to a decrease in bone density or changes in bone structure and strength. Osteoporosis mainly occurs in postmenopausal women and the elderly. In the treatment of osteoporosis, it is important to prevent bone loss and inhibit the formation of osteoclasts, which are involved in bone resorption. Research is needed to prevent and treat fractures caused by osteoporosis. In this study, we investigated the effect of isorhamnetin on RANKL-induced osteoclast differentiation. Isorhamnetin significantly inhibited osteoclast differentiation by effectively inhibiting transcription and translation of NFATc1, an essential component in the osteoclast differentiation process. Additionally, the mRNA expression of TRAP, DC-STAMP, and CTSK, genes related to osteoclast differentiation, was suppressed. Therefore, isorhamnetin has the potential to be used as a functional food and therapeutic agent for the treatment of osteoporosis.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalKorean Journal of Pharmacognosy
Issue number4
StatePublished - 2023

Bibliographical note

Publisher Copyright:
© 2023, Korean Society of Pharmacognosy. All rights reserved.


  • Isorhamnetin
  • NFATc1
  • Osteoclast
  • Osteoporosis


Dive into the research topics of 'Effect of Isorhamnetin on Inhibition of RANKL-induced Osteoclast Differentiation'. Together they form a unique fingerprint.

Cite this